Ashland (ASH) Q1 2026 earnings summary

Executive summary

• Q1 results showed solid performance and margin resilience despite ongoing demand softness in coatings and construction, with strong execution and disciplined cost actions supporting results.

• Life Sciences achieved healthy growth, driven by pharma demand and innovation; Personal Care remained stable, with biofunctional actives and microbial protection outperforming, while Specialty Additives and Intermediates faced muted demand.

• Net loss improved to $12 million from $165 million year-over-year, reflecting the absence of large impairment charges and improved operational performance.

• Operational challenges included the extended Calvert City outage and weather-related disruptions, with customer supply maintained but incremental costs incurred.

• Exited the quarter with improving momentum and expect continued progress on strategic priorities, supported by innovation and cost discipline.

Financial highlights

• Q1 sales were $386 million, down 5% year-over-year, mainly due to lower volume and the Avoca divestiture; excluding Avoca, sales declined 3%.

• Adjusted EBITDA was $58 million, down 5% year-over-year; margin held at 15%.

• Adjusted EPS (ex-intangible amortization) was $0.26, down 7% year-over-year; gross profit margin improved to 29.3%.

• Operating cash flow was $125 million, aided by a $103 million tax refund; free cash flow was $26 million, with nearly 50% conversion in a seasonally low quarter.

• Liquidity at quarter-end was ~$900 million; net debt $1.1 billion; net leverage 2.7x.

Outlook and guidance

• Fiscal 2026 adjusted EBITDA guidance narrowed to $400–$420 million; sales guidance $1,835–$1,905 million.

• Adjusted diluted EPS (excluding intangibles amortization) is projected to show double-digit growth; ongoing free cash flow conversion expected at ~50% of adjusted EBITDA, with $100 million in capex.

• $11 million of temporary impacts from Calvert City delay and weather disruptions expected in Q2; most volume impacts are recoverable, but timing is uncertain.

• Life Sciences and Personal Care expected to remain resilient; Specialty Additives and Intermediates to see gradual, regionally uneven recovery.

• Second half-weighted performance anticipated, with cost savings and innovation driving margin improvement.